Peripheral neuropathy in systemic vasculitides

Current Opinion in Rheumatology

Volumn 17, Issue 1, 2005, Pages 41-48

  Pagnoux, Christian ^a   Guillevin, Loïc ^a  

^a Université Paris V ^*  (France)

Author keywords

ANCA associated vasculitides; Mononeuritis multiplex; Peripheral nervous system involvement; Peripheral neuropathy; Polyarteritis nodosa; Systemic necrotizing vasculitis; Therapeutics

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOGLOBULIN; LAMIVUDINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; CELL INFILTRATION; CLINICAL FEATURE; CLINICAL TRIAL; CRANIAL NEUROPATHY; CRYOGLOBULINEMIA; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY CELL; MONONEUROPATHY MULTIPLEX; NERVE BIOPSY; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC VASCULITIS;

ANIMALS; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; VASCULITIS;

EID: 11344279995     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000145518.91595.2f     Document Type: Review

References (84)

1. Frohnert P, Sheps S: Long term follow-up study of periarteritis nodosa. Am J Med 1967, 43:8-14.
2. Moore PM, Cupps TR: Neurological complications of vasculitis. Ann Neurol 1983, 14:155-167.
3. Fauci AS, Haynes BF, Katz P, et al.: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
4. Pinching AJ, Lockwood CM, Pussell BA, et al.: Wegener's granulomatosis: observations on 18 patients with severe renal disease. Q J Med 1983, 52:435-460.
5. Guillevin L, Cohen P, Gayraud M, et al.: Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78:26-37.
6. Sehgal M, Swanson JW, DeRemee RA, et al.: Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc 1995, 70:337-341.
7. Guillevin L, Durand-Gasselin B, Cevallos R, et al.: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421-430.
8. Savage CO, Winearls CG, Evans DJ, et al.: Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985, 56:467-483.
9. Heuss D, Schlotter-Weigel B, Sommer C: [Diagnosis and therapy of vasculitic neuropathy: consensus statement of the German centers for neuromuscular disease] (in German). Fortschr Neurol Psychiatr 2003, 71:172-186. A good review on vasculitic peripheral neuropathy.
10. Caselli RJ, Hunder GG, Whisnant JP: Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988, 38:352-359.
11. Younger DS: Vasculitis of the nervous system. Curr Opin Neurol 2004, 17:317-336. An excellent review on nervous system involvement in vasculitides.
12. Antoine JC, Camdessanche JP: [Paraneoplastic peripheral neuropathies] (in French). Rev Neurol (Paris) 2004, 160:188-198.
13. Mahadevan A, Gayathri N, Taly AB, et al.: Vasculitic neuropathy in HIV infection: a clinicopathological study. Neurol India 2001, 49:277-283.
14. Nemni R, Sanvito L, Quattrini A, et al.: Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinemia. J Neurol Neurosurg Psychiatry 2003, 74:1267-1271. Study on 51 HCV-infected patients, 78% of whom had mixed cryoglobulinemia, showed that peripheral neuropathy is more frequent in patients with mixed cryoglobulinemia than in those without (45 vs 9%, respectively; P = 0.01).
15. Authier FJ, Bassez G, Payan C, et al.: Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003, 60:808-812. Study on 30 HCV-infected patients with peripheral neuropathy, 63% with mixed cryoglobulinemia, showed that peripheral neuropathy in these patients is mainly represented by distal axonal polyneuropathy and that inflammatory vascular infiltrates are present in 87% of the muscle-nerve biopsies, whereas genomic HCV RNA was detected in only 33% of the biopsies. The authors concluded that HCV neuropathy preferentially results from virus-triggered immune mechanisms rather than direct nerve infection.
16. Kanai K, Kuwabara S, Mori M, et al.: Leukocytoclastic-vasculitic neuropathy associated with chronic Epstein-Barr virus infection. Muscle Nerve 2003, 27:113-116.
17. Lortholary O, Généreau T, Guillevin L: [Viral vasculitis not related to HBV, HCV and HIV] (in French). Pathol Biol (Paris) 1999, 47:248-251.
18. Guillevin L, Lhote F, Gherardi R: The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumatol 1997, 9:31-36.
19. Harper L, Chin L, Daykin J, et al.: Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004, 60:671-675.
20. Siva A, Altintas A, Saip S: Bençet's syndrome and the nervous system. Curr Opin Neurol 2004, 17:347-357.
21. Puéchal X, Said G, Hilliquin P, et al.: Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis: a clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995, 38:1618-1629.
22. Said G, Lacroix C, Planté-Bordeneuve V, et al.: Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clincopathological study of 11 patients. Brain 2002, 125:264-275.
23. Said G: [Neurological manifestations of systemic necrotizing vasculitis] (in French). Rev Neurol (Paris) 2002, 158:915-918.
24. Mawrin C, Brunn A, Röcken C, et al.: Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) 2003, 105:365-372. Matrix metalloproteinases MMP-3 and MMP-9 are upregulated in vessel walls of patients with SLE and may be responsible for vascular damage and axonal and demyelinating neuropathy.
25. Bouche P, Leger JM, Travers MA, et al.: Peripheral neuropathy in systemic vasculitis: clinical and electrophysiologic study of 22 patients. Neurology 1986, 36:1598-1602.
26. Castaigne P, Brunet P, Hauw JJ, et al.: [Peripheral nervous system and panarteritis nodosa: review of 27 cases]. Rev Neurol (Paris) 1984, 140:343-352.
27. Moore PM: Vasculitis of the central nervous system. Semin Neurol 1994, 14:307-312.
28. Said G: Necrotizing peripheral nerve vasculitis. Neurol Clin 1997, 15:835-848.
29. Moore PM, Fauci AS: Neurologic manifestations of systemic vasculitis: a retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. Am J Med 1981, 71:517-524.
30. de Groot K, Schmidt DK, Arlt AC, et al.: Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001, 58:1215-1221.
31. Collins MP, Periquet MI: Prevalence of vasculitic neuropathy in Wegener granulomatosis. Arch Neurol 2002, 59:1333-1334.
32. Nishino H, Rubino FA, DeRemee RA, et al.: Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993, 33:4-9.
33. Masi AT, Hunder GG, Lie JT, et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33:1094-1100.
34. Hattori N, Mori K, Misu K, et al.: Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol 2002, 29:1408-1414.
35. Ng KK, Yeung HM, Loo KT, et al.: Acute fulminant neuropathy in a patient with Churg-Strauss syndrome. Postgrad Med J 1997, 73:236-238.
36. Allan SG, Towla HM, Smith CC, et al.: Painful brachial plexopathy: an unusual presentation of polyarteritis nodosa. Postgrad Med J 1982, 58:311-313.
37. Gomes C, L'heveder G, Vandhuick O, et al.: A case of cutaneous sensory neuropathy associated with Churg-Strauss syndrome. Joint Bone Spine 2003, 70:73-76. The authors report three illustrative cases, followed by a comprehensive review on cutaneous sensory neuropathy, which usually manifests as multiple, sharply demarcated areas of hypoesthesia with varying degrees of pain. This entity has mainly been described in leprosy, and sometimes develops in polyarteritis nodosa and Churg-Strauss syndrome.
38. Ryan MM, Tilton A, De Girolani U, et al.: Paediatric mononeuritis multiplex: a report of three cases and review of the literature. Neuromuscul Disord 2003, 13:751-756. Three cases are reported followed by a comprehensive review on peripheral neuropathies, especially mononeuritis multiplex, in childhood systemic vasculitides.
39. Tervaert JW, Kallenberg C: Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993, 19:913-940.
40. Ropert A, Metral S: Conduction block in neuropathies with necrotizing vasculitis. Muscle Nerve 1990, 13:102-105.
41. Schoeller T, Huemer GM, Shafighi M, et al.: Microsurgical repair of the sural nerve after nerve biopsy to avoid associated sensory morbidity: a preliminary report. Neurosurgery 2004, 54:897-901. The authors report preliminary results in three patients of their strategy of microsurgical repair of the sural nerve after nerve biopsy. Their technique combined excision of a shorter nerve biopsy (10 mm) that still assured enough material for conclusive pathological diagnosis, with sectioned nerve repair that prevented sensory disturbances. However, their results remain to be confirmed in more patients.
42. Davidson JR, Sundstrom WR: Sural nerve biopsy in systemic necrotizing vasculitis. Arthritis Rheum 1988, 31:149-150.
43. Collins MP, Mendell JR, Periquet MI, et al.: Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000, 55:636-643.
44. Said G, Lacroix-Ciaudo C, Fujimura H, et al.: The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988, 23:461-465.
45. Gherardi R, Belec L, Mhiri C, et al.: The spectrum of vasculitis in human immunodeficiency virus-infected patients: a clinicopathologic evaluation. Arthritis Rheum 1993, 36:1164-1174.
46. Moore PM: Neurological manifestations of vasculitis: update on immunopathogenic mechanisms and clinical features. Ann Neurol 1995, 37:S131-S141.
47. Fressinaud C, Jean I, Dubas F: [Necrotizing vasculitis of the peripheral nervous system: comparison of the axon cytoskeleton abnormalities with other types of neuropathies] (in French). Rev Neurol (Paris) 2003, 159:293-299. A good description of axon cytoskeleton abnormalities seen in vasculitic neuropathies, attesting to functional response to nerve fiber loss, which often exceeds 55% of all myelinated fibers in the section.
48. Vrancken AF, Notermans NC, Jansen GH, et al.: Progressive idiopathic axonal neuropathy: a comparative clinical and histopathological study with vasculitic neuropathy. J Neurol 2004, 251:269-278. This comparison of 10 patients with progressive idiopathic axonal neuropathy and 10 with vasculitic neuropathy showed that clinical features and outcome are quite similar in both groups, but that histologic differences exist. Biopsies from patients with progressive idiopathic axonal neuropathy showed only one to have vasculitis and four with ischemic injury or inflammation.
49. Bussone G, La Mantia L, Frediani F, et al.: Vasculitic neuropathy in panarteritis nodosa: clinical and ultrastructural findings. Ital J Neurol Sci 1986, 7:265-269.
50. Dyck PJ, Benstead TJ, Conn DL, et al.: Nonsystemic vasculitic neuropathy. Brain 1987, 110:843-853.
51. Collins MP, Periquet MI, Mendell JR, et al.: Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003, 61:623-630. An impressive retrospective study of 48 patients with nonsystemic nerve vasculitis, with precise clinical descriptions, treatment, and outcome data. Overall mortality was 10%, with a 5-year mortality rate of 13%. The reported results support the idea that these patients truly have systemic vasculitis.
52. Oh SJ: Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997, 15:849-863.
53. Said G, Lacroix C, Lozeron P, et al.: Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003, 126:376-385.
54. Griffin JW: Vasculitic neuropathies. Rheum Dis Clin North Am 2001, 27:751-760.
55. Lundborg G: Structure and function of the intraneural microvessels as related to trauma, edema formation, and nerve function. J Bone Joint Surg Am 1975, 57:938-948.
56. Satoi H, Oka N, Kawasaki T, et al.: Mechanisms of tissue injury in vasculitic neuropathies. Neurology 1998, 50:492-496.
57. + T cells), but not MMP-2, was found in nerve biopsies from eight patients with non-systemic nerve vasculitis and four with systemic vasculitic neuropathy.
58. Renaud S, Erne B, Fuhr P, et al.: Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies. Acta Neuropathol (Berl) 2003, 105:37-42. Expression of matrix metalloproteinases MMP-9 and MMP-2 was high in nerve biopsies from 11 patients with inflammatory or noninflammatory polyneuropathies, five of whom had vasculitis. This upregulated MMP-9 expression paralleled T-cell and macrophage infiltration, which suggests a possible role of MMP-9 as means for inflammatory cell to invade vessel walls.
59. Sundy JS, Haynes BF: Cytokines and adhesion molecules in the pathogenesis of vasculitis. Curr Rheumatol Rep 2000, 2:402-410.
60. Lindenlaub T, Sommer C: Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol (Berl) 2003, 105:593-602. Immunoreactivity with proinflammatory cytokines, interleukin-1β, interleukin-6, and TNF-α, was strong in sural nerve biopsies from 17 patients with vasculitic neuropathy, and correlated with the degrees of axonal degeneration, endoneurial inflammatory cell infiltration, and neuropathic pain.
61. Hu W, Mathey E, Hartung HP, et al.: Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of peripheral nerve. Neurology 2003, 61:1774-1779. Cyclo-oxygenases are key enzymes in propagating inflammatory responses. Cyclo-oxygenase-2 (but not cyclo-oxygenase-1) mRNA was more abundant in macrophages in sural nerve biopsies of patients with systemic vasculitic neuropathy, and was associated with increased serum levels of prostaglandins PGE2 and PGF2α.
62. Alpa M, Ferrero B, Cavallo R, et al.: [Anti-GM1 and anti-sulphatide antibodies in systemic idiopathic vasculitis, systemic lupus erythematosus and mixed cryoglobulinemia: serum detection and clinical and electrophysiological correlations] (in Italian). G Ital Nefrol 2002, 19:617-621.
63. Tai PC, Holt ME, Denny P, et al.: Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. BMJ (Clin Res Ed) 1984, 289:400-402.
64. Hattori N, Ichimura M, Nagamatsu M, et al.: Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999, 122:427-439.
65. Lanham JG, Elkon KB, Pusey CD, et al.: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63:65-81.
66. O'Donovan CA, Keogan M, Staunton H, et al.: Peripheral neuropathy in Churg-Strauss syndrome associated with IgA-C3 deposits. Ann Neurol 1992, 32:411.
67. Sablé R, Mahr A, Cohen P, et al.: Influence of antineutrophil cytoplasm antibodies (ANCA) on presentation of Churg-Strauss syndrome [abstract]. Arthritis Rheum 2003, 48:S208.
68. Pfister H, Ollert M, Fröhlich LF, et al.: Anti-neutrophil cytoplasmic autoantibodies (ANCA) against the murine homolog of proteinase 3 (Wegener's autoantigen) are pathogenic in vivo. Blood 2004, 104:1411-1418. An animal model was lacking to support a pathogenic role of antiproteinase 3 in ANCA-associated vasculitides, mainly Wegener granulomatosis. Immunorelevant antimouse-proteinase 3 autoantibodies were generated by immunizing mice-proteinase 3/mice-neutrophil elastase-deficient knockout mice with recombinant murine proteinase 3 (mPR3) and adjuvant. Local inflammation induced in wild-type female mice after intradermal injection of TNF-α was increased after systemic passive transfer of anti-mPR3. However, no inflammatory changes or vasculitic manifestations (in kidneys or lungs) were noted after intravenous injection of anti-mPR3 into wild-type male mice primed intraperitoneally with LPS before passive antimPR3 transfer, or in the absence of previously induced local inflammation.
69. Xiao H, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
70. Ford R, Sieckert R: Central nervous system manifestations of periarteritis nodosa. Neurology 1965, 15:114-122.
71. Kinyoun JL, Kalina RE, Klein ML: Choroidal involvement in systemic necrotizing vasculitis. Arch Ophthalmol 1987, 105:939-942.
72. Duran E, Merkel PA, Sweet S, et al.: ANCA-associated small vessel vasculitis presenting with ischemic optic neuropathy. Neurology 2004, 62:152-153.
73. Gayraud M, Guillevin L, Le Toumelin P, et al.: Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
74. Davies L, Spies JM, Pollard JD, et al.: Vasculitis confined to peripheral nerves. Brain 1996, 119:1441-1448.
75. Guilievin L, Lhote F, Gayraud M, et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
76. Pagnoux C, Cohen P, Mahr A, et al.: Treatment of Churg-Strauss syndrome with poor prognosis factor(s): results of a prospective randomized multicenter trial comparing corticosteroids and 6 vs. 12 pulses of cyclophosphamide [abstract]. Arthritis Rheum 2003, 48:S661.
77. Guillevin L, Cohen P, Mahr A, et al.: Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49:93-100. Patients with polyarteritis nodosa or microscopic polyangiitis and one or more poor prognosis factors according to the five-factor score had a higher event-free survival rate when treated with 12 cyclophosphamide pulses compared with six pulses (and no maintenance treatment).
78. Langford CA, Talar-Williams C, Barron KS, et al.: Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003, 114:463-469.
79. Jayne D, Rasmussen E, Andrassy K, et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
80. Guillevin L, Mahr A, Cohen P, et al.: Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004, 51:482-487.
81. Levy Y, Uziel Y, Zandman GG, et al.: Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003, 62:1221-1223. Vasculitic peripheral neuropathy resolved after intravenous immunoglobulin administration in four of six patients who had previously failed to respond to steroid therapy.
82. Jayne DR, Chapel H, Adu D, et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000, 93:433-439.
83. Donofrio PD: Immune-therapy of idiopaihic inflammatory neuropathies. Muscle Nerve 2003, 28:273-292. A comprehensive review of immunotherapy in inflammatory neuropathies, including vasculitides.
84. Guillevin L, Pagnoux C: Indications of plasma exchanges for systemic vasculitides. Therap Apher Dial 2003, 7:155-160.